Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2438 • 2017 ACR/ARHP Annual Meeting
Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice
L. Tweehuysen¹, V.J.B. Huiskes², B.J.F. Van den Bemt (PharmD, PhD)³, S. Teerenstra⁴, F.H.J. van den Hoogen⁵, C.H.M. van den Ende⁵ and A.A. Den Broeder⁵, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ³Pharmacy, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands, ⁴Biostatistics, Radboudumc, Nijmegen, Netherlands, ⁵Rheumatology, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands
Background/Purpose: Blinded transitioning from originator infliximab (INX) to biosimilar CT-P13 was not inferior to continuing INX treatment.1 Open label mandatory transitioning resulted in a slightly…
Abstract Number: 254 • 2017 ACR/ARHP Annual Meeting
Psoriatic Arthritis Sonographic Enthesitis Scores – Systematic Review of the Literature
Ofir Elalouf¹, Sibel Bakirci², Zahi Touma³, Melanie A Anderson⁴, Gurjit S. Kaeley⁵, Sibel Z. Aydin⁶ and Lihi Eder^7,8, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Fellow in Rheumatology, Antalya, Turkey, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵University of Florida, Ponte Vedra Beach, FL, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷Medicine, University of Toronto, Toronto, ON, Canada, ⁸Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is a prominent feature of spondyloarthropathy (SpA), including psoriatic arthritis (PsA). The evaluation of enthesitis has conventionally been conducted by clinical exam, a…
Abstract Number: 629 • 2017 ACR/ARHP Annual Meeting
Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?
Suneil Kapur¹, Proton Rahman², Michelle Teo³, Jodie Reis⁴, Rajwinder Dhillon⁵, Pauline Boulos⁶, Raman Rai⁷, Regan Arendse⁸, Julie Vaillancourt⁹, Emmanouil Rampakakis⁹, Allen J Lehman¹⁰, Francois Nantel¹¹ and Brendan Osborne¹¹, ¹University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Niagara Falls, ON, Canada, ⁶Private Practice, Dundas, ON, Canada, ⁷Private Practice, Hamilton, ON, Canada, ⁸University of Saskatchewan, Saskatoon, ON, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that treating patients earlier with biologics could improve disease outcomes. The aim of this analysis was to assess the impact…
Abstract Number: 2503 • 2017 ACR/ARHP Annual Meeting
Does Maastricht Ankylosing Spondylitis Enthesitis Scores Differ between Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis Patients?
Steffan Robstad Nilssen¹, Jintana B: Andersen¹, Hanne K. Vestaby¹, Glenn Haugeberg² and Brigitte Michelsen³, ¹Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Martina Hansens Hospital, Bærum, Norway, ³Dept. of Rheumatology, Hospital of Southern Norway Trust, kristiansand, Norway
Background/Purpose: The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an enthesitis index developed and validated as an outcome measure in ankylosing spondylitis (AS), but is…
Abstract Number: 342 • 2017 ACR/ARHP Annual Meeting
Health Related Quality of Life Is Comparable in Psoriatic Arthritis and Rheumatoid Arthritis Patients in Spite of Different Disease Activity. SF-36 Data from a Large Prospective Observational Multicentre Study
Brigitte Michelsen^1,2, Till Uhlig¹, Eirik K Kristianslund¹, Joseph Sexton¹, Elisabeth Lie¹, Karen M Fagerli³, Hilde B Hammer⁴, Glenn Haugeberg^5,6 and Tore K Kvien⁷, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Martina Hansens Hospital, Bærum, Norway, ⁶NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: It is well established that RA patients have lower health related quality of life (HRQoL) across several domains compared with the general population, whereas…
Abstract Number: 631 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry
Derek Haaland¹, Anna Jaroszynska², B Haraoui³, Suneil Kapur⁴, Jacqueline Stewart⁵, Wojciech Olsynzynski⁶, Keltie Anderson⁷, Raman Rai⁸, Michael Starr⁹, Alexander Tsoukas¹⁰, Eliofotisti Psaradellis¹¹, Emmanouil Rampakakis¹¹, Cathy Tkaczyk¹², Allen J Lehman¹³, Francois Nantel¹² and Brendan Osborne¹², ¹Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ²Private practice, Burlington, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵Penticton Regional Hospital, Penticton, BC, Canada, ⁶University of Saskatchewan, Saskatoon, ON, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Hamilton, ON, Canada, ⁹Rheumatology, McGill University, Pointe-Claire,, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that concomitant methotrexate therapy may increase the efficacy of biologic treatments. A scarcity of data exists on the benefits of…
Abstract Number: 2526 • 2017 ACR/ARHP Annual Meeting
Baseline Data from the Recent-Onset Psoriatic Arthritis Registry of the Spanish Society of Rheumatology
Rubén Queiro¹, Ana Laiz², Carlos Alberto Montilla-Morales³, Eva Galindez-Agirregoikoa⁴, Juan J. Bethencourt⁵ and Daniel Seoane⁶, ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology, HU. Santa Creu i San Pau, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁴Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Rheumatology, HU. Canarias, Sta. Cruz de Tenerife, Spain, ⁶Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
Background/Purpose: The natural history of psoriatic arthritis (PsA) is hardly known and the information regarding PsA prospective cohorts is very scarce worldwide. The information obtained…
Abstract Number: 596 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies
Vibeke Strand¹, Kurt de Vlam², Jose A Covarrubias-Cobos³, Philip J Mease⁴, Dafna D Gladman⁵, Thijs Hendrikx⁶, Elizabeth Kudlacz⁷, Daniela Graham⁷, Joseph Wu⁷, Joseph C Cappelleri⁷ and Ming-Ann Hsu⁷, ¹Stanford University, Palo Alto, CA, ²UZ Leuven, Leuven, Belgium, ³Unidad Reumatologica Las Americas S.C.P, Yucatán, Mexico, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Safety and efficacy were investigated in 2 Phase…
Abstract Number: 880 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study
Désirée van der Heijde¹, Dafna D Gladman², Oliver FitzGerald³, Arthur Kavanaugh⁴, Daniela Graham⁵, Cunshan Wang⁵ and Lara Fallon⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ⁴University of California San Diego School of Medicine, La Jolla, San Diego, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Canada, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Here, we evaluate radiographic progression in PsA patients…
Abstract Number: 2536 • 2017 ACR/ARHP Annual Meeting
Comparison of Quality-of-Life, Function and Psoriasis Measures in Minimal Disease Activity and DAS28 States in Routine Care of Patients with Psoriatic Arthritis
Catherine Hughes, Nora Ng, Toby Garrood and Bruce Kirkham, Rheumatology, Guy's & St Thomas NHS Foundation Trust, London, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) often occurs with skin psoriasis (PsO). Disease activity can be measured using several tools including Minimal Disease Activity (MDA/VLMDA) or 28…
Abstract Number: 600 • 2017 ACR/ARHP Annual Meeting
Low Rates of Major Adverse Cardiac Events, Malignancies, and Serious Infections in Subjects with Psoriasis and Psoriatic Arthritis Treated with Apremilast for ≥156 Weeks: Pooled Analysis from the Esteem and Palace 1-3 Phase 3 Trials
Arthur Kavanaugh¹, Matthias Augustin², Eric Lespessailles³, Kim A. Papp⁴, Maria Paris⁵, Rongdean Chen⁵, Dafna D Gladman⁶, David M. Pariser⁷ and Ketty Peris⁸, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Institute for Health Care Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ³University of Orleans, Orleans, France, ⁴Probity Medical Research, Waterloo, ON, Canada, ⁵Celgene Corporation, Summit, NJ, ⁶Toronto Western Hospital, Toronto, ON, Canada, ⁷Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, ⁸Catholic University of Rome, Rome, Italy
Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, was effective in phase 3, randomized, placebo (PBO)-controlled trials assessing treatment of moderate to severe plaque psoriasis (ESTEEM…
Abstract Number: 884 • 2017 ACR/ARHP Annual Meeting
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: An Integrated Analysis across Phase 3 and Long-Term Extension Studies
Dafna D Gladman¹, Christina Charles-Schoeman², Iain B. McInnes³, Douglas J. Veale⁴, Bruce Thiers⁵, Daniela Graham⁶, Cunshan Wang⁶, Thomas Jones⁷, Robert Wolk⁶ and Ryan DeMasi⁷, ¹Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of California, Los Angeles, Los Angeles, CA, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴St. Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Medical University of South Carolina, Charleston, SC, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Cardiovascular (CV) disease and cardiometabolic syndrome are common comorbidities/causes of mortality in patients (pts) with psoriatic arthritis (PsA). Tofacitinib is an oral Janus kinase…
Abstract Number: 2554 • 2017 ACR/ARHP Annual Meeting
Disease Activity in Psoriatic Arthritis-ESR Index Maybe a Valid Tool to Evaluate Disease Activity in Patients with Psoriatic Arthritis When CRP Is Not Available
Andrea Lujan Coronel Ale¹, Emilce E Schneeberger¹, Osvaldo Luis Cerda¹, Cecilia Zaffarana¹, Marina Natalia Fornaro², Margarita Landi¹ and Gustavo Citera³, ¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ²Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, buenos aires, Argentina, ³Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: DAPSA is a composite index to assess disease activity in patients with Psoriatic Arthritis (PsA) which includes joint count 66/68, pain and patient´s global…
Abstract Number: 10L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Dafna D Gladman¹, William Rigby², Valderilio F Azevedo³, Frank Behrens⁴, Ricardo Blanco⁵, Andrzej Kaszuba⁶, Elizabeth Kudlacz⁷, Cunshan Wang⁷, Sujatha Menon⁷, Thijs Hendrikx⁸ and Keith S Kanik⁷, ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ³Federal University of Parana and Edumed Health Research Center and Biotech, Curitiba, Brazil, ⁴Johann Wolfgang Goethe University, Frankfurt, Germany, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁶Specialstyczne Gabinety Lerkarskie "DERMED", Lodz, Poland, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA. In this first study of tofacitinib in patients (pts) with active…
Abstract Number: 1676 • 2016 ACR/ARHP Annual Meeting
Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gia Deyab¹, Ingrid Hokstad², Stefan Agewall³, Torstein Lyberg⁴, Jon Elling Whist⁵, Milada Cvancarova Småstuen⁶, Gunnbjørg Hjeltnes⁷ and Ivana Hollan^8,9,10,11, ¹Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, ²Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, ³University of Oslo, Oslo, Norway, ⁴Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁵Innlandet Hospital Trust, Lillehammer, Norway, ⁶Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, ⁷Medicine, Innlandet Hospital Trust, Lillehammer, Norway, ⁸Harvard Medical School, Boston, MA, ⁹Department of Medicine, Brigham and Women's Hospital, Boston, MA, ¹⁰Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹¹Innlandet Hospital Trust, Brumunddal, Norway
Background/Purpose: Inflammatory rheumatic diseases (IRDs) are associated with accelerated atherosclerosis, which progression is related to inflammation (1). One of the first stages in atherogenesis is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].